 |
Previous Article | Next Article 
The Journal of Neuroscience, September 15, 1999, 19(18):7983-7990
Relative Contribution of Endogenous Neurotrophins in Hippocampal
Long-Term Potentiation
Guiquan
Chen,
Roland
Kolbeck,
Yves-Alain
Barde,
Tobias
Bonhoeffer, and
Albrecht
Kossel
Max-Planck-Institut für Neurobiologie, D-82152
München-Martinsried, Germany
 |
ABSTRACT |
Recent evidence has shown that brain-derived neurotrophic factor
(BDNF) is involved in hippocampal long-term potentiation (LTP). Because
the reagents used in acute experiments react not only with BDNF but
also with neurotrophin-4/5 (NT4/5) and neurotrophin-3 (NT3), we
examined the involvement of these neurotrophins in LTP using two highly
specific, function-blocking monoclonal antibodies against BDNF and NT3,
as well as a TrkB-IgG fusion protein. Our results show that NT3
antibodies did not have any effects on LTP. However, both TrkB-IgG
fusion proteins and BDNF antibody similarly reduced LTP, suggesting
that only BDNF but no other ligands of the TrkB-receptor are likely to
be involved in LTP induction. The reduction in LTP depended on the
inducing stimuli and was only observed with theta-burst stimulation
(TBS) but not with tetanic stimulation. We further observed that LTP
was only reduced if BDNF was blocked before and during TBS stimulation,
and BDNF antibodies did not affect early or late stages of LTP if they were applied 10, 30, or 60 min after TBS stimulation. These results point toward a specific and unique role of endogenous BDNF but not of
other neurotrophins in the process of TBS-induced hippocampal LTP.
Additionally, they suggest that endogenous BDNF is required for a
limited time period only shortly before or around LTP induction but not
during the whole process of LTP.
Key words:
BDNF; NT3; NT4/5; monoclonal antibodies; TrkB-IgG fusion
protein; LTP
 |
INTRODUCTION |
Neurotrophins are proteins that
control the survival and differentiation of many types of neurons
during development (Davies, 1994 ; Lewin and Barde, 1996 ). In addition,
there is increasing evidence indicating that neurotrophins are also
involved in activity-dependent neuronal plasticity in the developing
CNS (for review, see Lo, 1995 ; Thoenen, 1995 ; Berninger and Poo,
1996 ; Bonhoeffer, 1996 ). Compared with NGF, brain-derived neurotrophic
factor (BDNF), and neurotrophin-3 (NT3), mRNAs are highly
expressed in the hippocampus and neocortex (Wetmore et al., 1989 ;
Ernfors et al., 1990 ; Hofer et al., 1990 ; Maisonpierre et al., 1990 ),
and the expression of BDNF is tightly regulated by neuronal activity
(Zafra et al., 1990 , 1991 ; Castrén et al., 1992 ; Knipper et al.,
1994 ; for review, see Lindholm et al., 1994 ). Interestingly,
tetanization, a stimulation paradigm used to induce long-term
potentiation (LTP) in the hippocampus, can induce both BDNF and NT3
mRNA expression in different hippocampal areas (Patterson et al., 1992 ;
Dragunow et al., 1993 ). Also, the release of neurotrophins is dependent
on neuronal activity (Blöchl et al., 1995 ; Blöchl and
Thoenen, 1995 ; Griesbeck et al., 1995 ). Using BDNF and NT3, Lohof et
al. (1993) were the first to show a direct influence of exogenous
neurotrophins on synaptic transmission in neuromuscular synapses in
developing Xenopus. Later, several reports demonstrated that
acute application of exogenous BDNF, neurotrophin-4/5 (NT4/5), or NT3
can alter or potentiate synaptic transmission in rat hippocampal
cultures and slices (Lessmann et al., 1994 ; Kang and Schuman, 1995 ;
Levine et al., 1995 ). Although these experiments indirectly suggested
that neurotrophins can participate in synaptic plasticity, work with
mice carrying a null mutation in the BDNF gene showed that the lack of
endogenous BDNF leads to drastically impaired LTP (Korte et al., 1995 ;
Patterson et al., 1996 ) and to a limited capability of these animals to perform certain learning tasks (Linnarsson et al., 1997 ). Importantly, it was also shown that reexpression of the BDNF gene (Korte et al.,
1996 ) or treatment of slices with recombinant BDNF (Patterson et al.,
1996 ) were both able to restore LTP in slices of these mutant mice
within <14 hr, making unspecific developmental deficits unlikely as an
explanation for impaired LTP.
An additional approach to determine the involvement of endogenous
neurotrophins in LTP is to block their function acutely in slices from
wild-type animals. Two recent studies used a TrkB-IgG fusion protein
(FP) and antibodies (Abs) against the TrkB receptor to block the
ligands or the function of the TrkB receptor. This led to impaired LTP
in slices from rat hippocampus (Figurov et al., 1996 ; Kang et al.,
1997 ). Because both BDNF and NT4/5 can interact with the TrkB receptor,
these experiments still leave the issue unresolved as to which of the
two particular ligands actually contribute to LTP. The situation is
further complicated by the fact that TrkB FPs are not selective for
BDNF and NT4/5 but also bind NT3 (Shelton et al., 1995 ). The
availability of specific, function-blocking monoclonal antibodies
against BDNF and NT3 allowed us to acutely and selectively interfere
with these neurotrophins and to determine their function in hippocampal
LTP. We compared their effects on LTP with those of TrkB-IgG FPs and assessed the time period relative to the induction of LTP during which
neurotrophins need to be available.
 |
MATERIALS AND METHODS |
Slice preparation. Hippocampal transversal slices
(400-µm-thick) were prepared from male wild-type mice of SV129 strain
(4-8 weeks old) using conventional techniques (Korte et al., 1995 ) and
maintained under standard conditions [medium contained (in mM): 124 NaCl, 3 KCl, 1.25 KH2PO4, 2 Mg2SO4, 26 NaHCO3, 2.5 CaCl2, and 10 glucose; at room temperature) and
gassed with 95% O2 and 5%
CO2. Slices were allowed to recover in an
incubation chamber for at least 1.5 hr at room temperature before they
were transferred to the perfusion chamber and used for the
electrophysiological experiments.
Perfusion of slices with antibodies. The following
antibodies were used for LTP experiments: (1) a TrkB receptor body,
which is a fusion protein between the extracellular domain of the chick TrkB receptor and the Fc part of a human IgG antibody (Dechant et al., 1993 ); (2) a mouse monoclonal antibody (MAB) (clone #21, IgG2B) raised against BDNF, characterized by its
function blocking action with the same specificity as MAB clone #9
described by Kolbeck et al. (1999) ; and (3) a mouse monoclonal
function-blocking NT3 antibody (IgG1) (Gaese et
al., 1994 ). Antibody solutions were freshly prepared in perfusate
artificial CSF (ACSF) from frozen antibody aliquots. The final
concentration used for TrkB-IgG fusion protein, anti-BDNF, or anti-NT3
antibody was 4 µg/ml. In the course of this study, we realized that
it is of paramount importance to counteract adhesion of the antibodies
to surfaces of beakers, tubing, etc. Therefore, tubing and
beakers were siliconized for 1 hr and dried afterward. Before the
actual experiments, siliconized tubing was washed extensively with
fresh ACSF for 30 min. Additionally, BSA (0.1 mg/ml) was added to the
antibody, as well as to the control solutions. To test for the presence
and stability of the antibodies in the perfusion solution, the level of
antibodies was determined from probes taken at different time points
during perfusion using a specific enzyme immunoassay (ELISA). All
experiments were performed in a blind way; the experimenter performing
the electrophysiological recordings did not know what type of solution
was added to the perfusion medium. A closed-loop perfusion system was
used for all experiments with a total volume of 30 ml of perfusion
medium. During preincubation of slices with either antibody or control solution, perfusion rates were alternated between fast rate at 40 ml/min, which potentially facilitates diffusion of exogenously applied
substances into slices (Kang et al., 1996 ), and slow rate at 1 ml/min
to prevent possible damage to the slices. For electrophysiological recordings, perfusion rate was kept constant at 1 ml/min during all
experiments. After each recording, tubings and the recording chamber
were extensively washed with fresh ACSF for 5-10 min.
Electrophysiology. Recordings were performed at 32°C.
Slices were transferred from the incubation chamber to the recording chamber. In the pretreatment LTP experiments, they were perfused for 1 hr in either control or antibody-containing medium before electrophysiological recordings were started. In the other experiments in which antibody or control aliquots were added at different time
points after theta-burst stimulation (TBS), the control or anti-BDNF
antibody solutions were washed into the recording chamber at 10, 30, or
60 min after TBS, respectively. Control and antibody experiments were
performed at the same experimental day. Field EPSPs (fEPSPs) of
CA1 apical dendrites were recorded extracellularly with a glass
electrode filled with 3 M NaCI solution
(resistance of 4-10 M ) at a depth of ~120 µm below the slice
surface. Two stimulating electrodes (monopolar, coated tungsten) were
placed on either side of the recording electrode (within 200-400
µm). Stimuli were delivered alternating between these two independent Schaffer collateral-CA1 pathways, one serving as test and the other as
control pathway, at a frequency of 0.1 Hz to each pathway. Stimulation
in each pathway was set to elicit a fEPSP with an amplitude of
~40-50% of maximum. LTP was induced in the testing pathway by
either tetanus consisting of 3 × 30 pulses (100 Hz, 5 sec
intertrain interval) or theta-burst stimulation of three trains (10 sec intertrain interval), each consisting of 15 [200 msec
interstimulus interval (ISI)] × 4 pulses (100 Hz).
Data analysis. Data were collected with a program written in
LABVIEW (National Instruments, Austin, TX) and stored onto computer. The initial slope and amplitude of fEPSPs evoked by stimulation of the
Schaffer collateral afferents was observed online but later reanalyzed
off-line. Responses in each experiment were normalized to baseline,
which was defined as the mean value obtained in 100 responses before
tetanus or TBS, and shown as mean ± SEM. Experiments were
excluded from the experimental data set if (1) the baseline of testing
pathway was unstable (variability more than ±20%), or (2) the
control pathway or the testing pathway were unstable or showed an
apparent drift (variability more than ±20%). The "identity" of
all slices was not revealed to the experimenter performing the
electrophysiological recordings before the analysis was completed. As
statistical test, the unpaired one-tailed Student's t test
was used. A one-tailed test was chosen because the effect of the
antibody and fusion protein treatments, if any, should be directional
i.e., with smaller LTP in the experimental group than the respective
controls. Significance levels are indicated in text. p > 0.05 were considered as not significant.
 |
RESULTS |
Effects of TrkB-IgG fusion protein and BDNF antibodies on basal
synaptic transmission
We first tested whether the basal synaptic transmission at the
Schaffer collateral-CA1 synapses was affected by pretreatment of the
slices with TrkB-IgG FP or anti-BDNF antibody. Basal synaptic transmission was assessed in two ways. First, we measured the input-output curves of synaptic strength by plotting the slope of the
fEPSPs versus the stimulus strength in control and antibody-fusion protein-treated slices. As shown in Figure
1A, the size of field EPSP slope in TrkB-IgG FP-treated slices was not significantly lower
than in the controls for all the stimuli used. Also, incubation of
slices with anti-BDNF monoclonal antibody for 1 hr did not show any
effect on the input-output curves (Fig. 1B). We also compared the maximal response that we could elicit in control and
antibody treated slices. The maximal slope of field EPSPs under
treatments with both antibodies was also not significantly reduced from
control slices (data not shown). The data above suggest that there is
no deficit in basal synaptic transmission after acutely blocking
endogenous BDNF with BDNF antibodies or other TrkB ligands with a
TrkB-IgG fusion protein in hippocampal slices.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 1.
Basal synaptic transmission at the Schaffer
collateral-CA1 pathway of hippocampal slices is not affected by
treatment with TrkB-IgG fusion protein or BDNF antibody. The slope of
field EPSPs was plotted against stimulus strength (in microamperes).
A, TrkB-IgG fusion protein (triangles,
dotted line; n = 7 slices, 4 mice)
and controls (diamonds, solid line;
n = 8 slices, 4 mice) (p > 0.2). B, BDNF antibody (triangles,
dotted line; n = 8 slices, 4 mice)
and controls (diamonds, solid line;
n = 7 slices, 4 mice) (p > 0.3).
|
|
Effects of TrkB-IgG fusion proteins and BDNF antibodies on
short-term plasticity
We next examined the presynaptic function in
antibody-treated slices checking two forms of short-term synaptic
plasticity in the Schaffer collateral-CA1 pathway of hippocampal
slices: paired-pulse facilitation (PPF) and post-tetanic potentiation (PTP). First, we measured PPF in control and antibody-treated slices.
PPF is a form of presynaptic short-term plasticity in which the
response of a neuron to the second of two consecutive stimuli
with a given ISI to the first one is increased (Katz and Miledi, 1968 ;
Zucker, 1989 ). One hour after perfusion of the slices with control or
antibody solutions, we tested PPF by using ISIs of 30, 40, 60, and 100 msec in control and antibody-treated slices. We found that PPF was
reduced in neither TrkB-IgG fusion protein-treated slices compared with
control slices ( p > 0.2 for all ISIs; one-tailed t test) (Fig.
2A) nor in BDNF
antibody-treated slices (p > 0.2 for all ISIs;
one-tailed t test) (Fig. 2B). No deficits
in PPF suggest that presynaptic forms of short-term plasticity stay
normal after blocking endogenous BDNF or other TrkB ligands in
antibody-treated slices. These results are consistent with our earlier
findings in BDNF mutant mice (Korte et al., 1995 ). We also measured
PTP, another form of short-term plasticity induced by tetanic
stimulation, by averaging the EPSPs during the first minute after
tetanic stimulation (average of six EPSPs) and calculating the ratio
between this and the baseline value. We found that the size of PTP
immediately after tetanic stimulation was not significantly reduced in
TrkB receptor body-treated slices (TrkB-IgG, 301 ± 43%;
n = 6; control, 281 ± 20%; n = 6; p > 0.3; one-tailed t test) (Fig.
3A), as well as BDNF
antibody-treated slices compared with their controls (BDNF Ab, 324 ± 27%; n = 7; control, 264 ± 25%;
n = 7; p > 0.08; one-tailed t test) (Fig.
4A). Together, the
above results indicate that neither TrkB-IgG FP nor BDNF antibody alter
short-term plasticity in hippocampal slices, thus suggesting that
presynaptic neurotransmitter release is not disturbed by blocking
ligands of TrkB receptor.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 2.
Short-term plasticity measured by PPF
remains normal and unaffected at the Schaffer collateral-CA1 pathway
of hippocampal slices after treatment with TrkB-IgG fusion protein or
BDNF antibody. Plot depicting the percent ratio of responses to the
second pulse relative to the first one. Pairs of pulses were delivered
at interpulse intervals of 30, 40, 60, and 100 msec. A,
TrkB-IgG fusion protein-treated slices (triangles,
dotted line; n = 7 slices, 4 mice) versus control slices (diamonds, solid
line; n = 8 slices, 4 mice). B,
BDNF antibody-treated slices (triangles, dotted
line; n = 8 slices, 4 mice) versus control
slices (diamonds, solid line;
n = 7 slices, 4 mice).
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Figure 3.
Effects of blocking all endogenous TrkB ligands on
LTP. Pretreatment with TrkB-IgG fusion protein for 1 hr reduces LTP in
a stimulus-dependent manner; only LTP induced by TBS at the Schaffer
collateral-CA1 synapses of hippocampal slices is affected but not LTP
induced by tetanic stimulation. Field EPSP slopes were plotted as
percent of baseline (mean ± SEM). Straight black
line represents the presence of TrkB-IgG fusion protein.
First data point after LTP induction represents PTP.
A, Tetanus-induced LTP and the effects of TrkB-IgG
fusion protein (TrkB-IgG, n = 6 slices, 4 mice;
control, n = 6 slices, 4 mice). B,
TBS-induced LTP and the effects of TrkB-IgG fusion protein (TrkB-IgG,
n = 7 slices, 4 mice; control,
n = 5 slices, 4 mice).
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Figure 4.
Effect of selectively blocking endogenous BDNF on
LTP. Pretreatment with BDNF antibody for 1 hr significantly reduces LTP
induced by TBS but not by tetanic stimulation. A,
Effects of BDNF antibody on tetanus-induced LTP (BDNF Ab,
n = 7 slices, 4 mice; control,
n = 7 slices, 4 mice). B, Effects of
BDNF antibody on TBS-induced LTP (BDNF Ab, n = 6 slices, 4 mice; control, n = 7 slices, 4 mice).
|
|
TrkB-IgG fusion protein attenuates LTP induced by TBS but
not by tetanus
At present, two kinds of LTP-inducing stimuli, tetanus and
TBS, are widely used to induce LTP in hippocampal slices. Both protocols were applied in our experiments in combination with the
blockade of neurotrophins. First, we checked the effect of TrkB-IgG FP
on LTP induced by tetanus. After the slice was superfused by medium
containing either 4 µg/ml FP or the control solution for 1 hr, three
trains of 100 Hz tetani were delivered to the Schaffer collateral-CA1
synapses to induce LTP. We found that LTP measured 1 hr after tetanus
was not reduced by the TrkB-IgG FP compared with control slices
(average slope of fEPSPs to baseline 55-60 min after tetanus:
TrkB-IgG, 157 ± 24%; n = 6; control, 135 ± 10%; n = 6; p > 0.2; one-tailed
t test) (Fig. 3A). TBS constitutes another
important stimulus protocol to induce LTP. Compared with tetanus,
TBS is a weak stimulus, and it is designed to mimic the theta
rhythm in the hippocampus. We therefore also used this stimulus paradigm to induce LTP. In contrast to the tetanus-induced LTP, we
found a significant reduction in LTP 1 hr after TBS in TrkB-IgG fusion
protein-treated slices compared with their controls (average slope of
fEPSPs to baseline 55-60 min after TBS: TrkB-IgG, 132 ± 14%;
n = 7; control, 167 ± 12%; n = 5; p < 0.04; one-tailed t test) (Fig.
3B). Interestingly, PTP was also significantly lower in the
treatment group, similar to the results of Figurov et al. (1996) , who
used a similar stimulation paradigm to test the effects of TrkB-IgG
fusion proteins. Synaptic transmission in the control pathway remained
unaffected (average slope of fEPSPs to baseline in the nontetanized
pathway 1 hr after TBS: TrkB-IgG, 93 ± 5%; n = 7; control, 93 ± 3.0%; n = 5; p > 0.45; one-tailed t test). This confirms previous reports
(Figurov et al., 1996 ; Kang et al., 1997 ) suggesting that ligands of
TrkB receptor might have direct effects on TBS-induced LTP.
BDNF antibody reduces LTP induced by TBS but not by tetanus
The experiments above showed that blocking ligands of TrkB
receptor reduced TBS-induced LTP. However, it still remains unclear which of the endogenous ligands of the TrkB receptor (BDNF, NT4/5, or
both) participate in the process of LTP. Therefore, in the following
experiments, we also used a specific monoclonal antibody against BDNF
to determine whether blocking endogenous BDNF alone will affect
hippocampal LTP in the same way. As before, we first checked the effect
of BDNF antibody on tetanus-induced LTP and found that, in the presence
of 4 µg/ml BDNF antibody, LTP was again not significantly reduced
(average slope of fEPSPs to baseline 55-60 min after tetanus: BDNF Ab,
138 ± 16%; n = 7; control, 151 ± 18%;
n = 7; p > 0.3; one-tailed
t test) (Fig. 4A). Slices pretreated with
4 µg/ml BDNF antibody for 1 hr and stimulated with TBS, however, showed significant reduction in LTP (average slope of fEPSPs to baseline 55-60 min after TBS: BDNF Ab, 122 ± 7%;
n = 6; control, 157 ± 12%; n = 7; p < 0.018; one-tailed t test) (Fig.
4B), whereas basal synaptic transmission in the
control pathway remained unaffected (average slope of fEPSPs to
baseline in the nontetanized pathway 55-60 min after TBS: BDNF Ab,
85 ± 1%; n = 4; control, 90 ± 4%; n = 4; p > 0.2; one-tailed
t test). The difference between the two groups became
apparent immediately after TBS. Thus, PTP after TBS stimulation was
reduced by application of BDNF antibodies in contrast to PTP after
tetanic stimulation. Together, these results show that hippocampal LTP
is significantly reduced by the BDNF-antibody and to a comparable
degree as seen with TrkB-IgG FP.
Anti-NT3 antibody does not block LTP induced by either tetanus
or TBS
Previous studies that applied neurotrophins exogenously to the
medium have suggested a direct role for NT3 in the process of LTP. We
therefore asked the question whether blocking of endogenous NT3 by a
specific function-blocking monoclonal antibody alters the induction or
expression of hippocampal LTP. First, we checked the antibody effect on
basal synaptic transmission and short-term plasticity. We found that
neither basal synaptic transmission nor short-term synaptic plasticity
in hippocampal slices were affected (data not shown). Second, we
pretreated slices with antibodies for 1 hr and recorded LTP in control
and NT3 antibody-treated slices. We also did not find any significant
reduction effect in NT3 antibody-treated slices on either
tetanus-induced LTP (average slope of fEPSPs to baseline 55-60 min
after tetanus: NT3 Ab, 160 ± 12%; n = 14;
control, 182 ± 10%; n = 15; p > 0.09; one-tailed t test) (Fig.
5A) or TBS-induced LTP
(average slope of fEPSPs to baseline 55-60 min after TBS: NT3 Ab,
190 ± 11%; n = 13; control, 194 ± 16%;
n = 11; p > 0.2; one-tailed
t test) (Fig. 5B). These results indicate that
endogenous NT3 seems not to be directly involved in hippocampal
LTP.

View larger version (25K):
[in this window]
[in a new window]
|
Figure 5.
Effect of blocking endogenous NT3 on LTP. NT3
antibody does not affect LTP induced by either tetanus or TBS.
Pretreatment time for slices was again 1 hr before recordings were
started. A, Effects of NT3 antibody on tetanus-induced
LTP (NT3 Ab, n = 14 slices, 10 mice; control,
n = 15 slices, 9 mice). B, Effects
of NT3 antibody on TBS-induced LTP (NT3 Ab, n = 13 slices, 10 mice; control, n = 11 slices, 8 mice).
|
|
BDNF antibody does not significantly reduce LTP when applied
after TBS
Because the data thus far indicate that endogenous BDNF but not
NT-4/5 or NT3 directly participates in TBS-induced LTP, we were then
interested in determining the time during which BDNF needs to be
present. Is endogenous BDNF required during a longer time period before
and after LTP induction, arguing for a more permissive role, or might
it be only required during the time period of LTP induction, in line
with an instructive role of the protein? To address this question, we
washed the BDNF antibody into the recording chamber at different time
points (10, 30, and 60 min after delivery of TBS), and LTP was recorded
for at least 1 hr after antibody infusion. In these experiments, we
only used slices with a strong initial PPF (>200% at 30 msec ISI),
because these slices expressed reliably more stable and higher levels of LTP, important for long-term recordings. When the BDNF antibody was
applied 10 min after TBS, we found that early phase LTP in BDNF
antibody-treated slices was reduced; however, this reduction was not
significant (average slope of fEPSPs to baseline 90 min after TBS: BDNF
Ab, 177 ± 23%; n = 9; control, 223 ± 24%;
n = 8; p > 0.1; one-tailed
t test; control pathway: BDNF Ab, 84 ± 5%
n = 6; control, 97 ± 8%; n = 5;
p > 0.1) (Fig.
6A). Although the
greater variability of the data in this experiment require a cautious
interpretation and conclusion about the absence of a significant
reduction effect, it is important to note that wash-in of the
antibodies does not cause any increase in the difference between the
two groups. Second, the smaller LTP present in the antibody group
already exists from the very beginning after TBS, that is, at a time
before the antibodies were washed in. Together, this experiment suggest
that, after induction, endogenous BDNF does not seem to be required
anymore for the maintenance of early phase LTP. We also tested whether
blocking of BDNF had effects on the later periods of LTP. For this,
antibodies were also applied 30 or 60 min after TBS, and
long-term recordings (>3 hr) were made. There was no
significant reduction of long-lasting LTP in antibody-treated slices
(30 min after treatment-average slope of fEPSPs to baseline 180 min
after TBS: BDNF Ab, 164 ± 32%; n = 6; control,
167 ± 9%; n = 4; p > 0.5;
one-tailed t test; 60 min after treatment-average slope of
fEPSPs to baseline 180 min after TBS: BDNF Ab, 179 ± 21%;
n = 5; control, 180 ± 38%; n = 5; p > 0.5; one-tailed t test) (Fig.
6B). These results strongly suggest that, after the
delivery of TBS, endogenous BDNF is not required, for neither early nor
medium-to-late phase LTP.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 6.
Effect on LTP is dependent on the time when
endogenous BDNF is blocked by the antibodies. A, BDNF
antibodies do not reduce LTP significantly when applied 10 min after
TBS. B, Applications 30 or 60 min after TBS also do not
affect LTP and its maintenance. Field EPSP slopes were plotted as
percent of baseline. Bars indicate level of LTP at the
end of each recording averaged over a 5 min period. Late phase LTP (3 hr after TBS) was measured for 30 and 60 min treatment groups (10 min
group: BDNF Ab, n = 9 slices, 7 mice; control,
n = 8 slices, 7 mice; 30 min group: BDNF Ab,
n = 6 slices, 6 mice; control,
n = 4 slices, 4 mice; 60 min group: BDNF Ab,
n = 5 slices, 5 mice; control,
n = 5 slices, 5 mice).
|
|
 |
DISCUSSION |
Although several recent studies have focused on the role of BDNF
in neurotransmission and LTP within the hippocampus, data on the
potential involvement of other neurotrophins are sparse and mainly
based on experiments using application of exogenous neurotrophins. With
regard to potentiation of synaptic strength in CA1 (the area
investigated in our study), BDNF and NT3 seem to be equally effective
(Kang and Schuman, 1995 ). In this study, we specifically addressed the
question as to what role the endogenous neurotrophins BDNF,
NT4/5, and NT3 play in the process of LTP.
Specificity of neurotrophic action on LTP
Direct evidence for the involvement of endogenous BDNF on LTP has
been obtained by experiments using BDNF knock-out mice that show
greatly reduced enhancement (Korte et al., 1995 ). Unlike NT3 /
animals, BDNF null mutants survive long enough for the kind of
experiments to be performed in the postnatal hippocampus. LTP can be
"rescued" in BDNF / and +/ animals by incubating these slices
either in recombinant BDNF (Patterson et al., 1996 ) or by reintroducing
the BDNF gene (Korte et al., 1996 ). Additionally, two recent studies
demonstrate that blocking the endogenous ligands of the TrkB receptor
in slices by TrkB-IgG FP also affects LTP (Figurov et al., 1996 ; Kang
et al., 1997 ). These studies left the question unresolved as to whether
the effect was obtained by blockade of endogenous BDNF, by blockade of
NT4/5, or both. Although the relative abundance of BDNF could be taken
as evidence for a significant physiological role (Ernfors et al., 1990 ;
Hofer et al., 1990 ; Martinez et al., 1998 ), it is clear that NT4/5 is also expressed in the hippocampus during all stages of development (Klein et al., 1992 ; Timmusk et al., 1993 ). Experiments using a
TrkB-IgG FP and a BDNF-specific antibody enabled us to distinguish between the roles of NT4/5 and BDNF in hippocampal LTP. Although TrkB
fusion protein bind equally to NT4/5 and BDNF and with slightly lower affinity, even to NT3 (Shelton et al., 1995 ), the similar reduction in LTP seen in response to the fusion protein and the BDNF-specific antibody argues against a direct and necessary
involvement of NT-4/5 in hippocampal LTP.
So far, no clear evidence is available on the role of endogenous NT3 in
the process of hippocampal CA1 LTP. Although NT3 and TrkC are strongly
expressed early in development, the expression of both is weaker but
still present within the adult hippocampus (Ernfors et al., 1990 ;
Maisonpierre et al., 1990 ; Lamballe et al., 1994 ; Martinez et al.,
1998 ). Previous studies have shown that exogenous NT3 added to the
perfusion medium of slices leads to a fast potentiation of synaptic
strength in the CA1 region of hippocampus, similar to the effects
obtained with BDNF (Kang and Schuman, 1995 ), suggesting that NT3 could
be potentially as important as BDNF for LTP. The experiments presented
here tested the role of endogenous NT3 in LTP by blocking its function
through a specific antibody. They show that blocking of NT3 affects
neither TBS- nor tetanus-induced LTP. Given that both the NT3 and the BDNF antibodies are IgG molecules, their diffusion properties should be
very similar, and both should reach the same sites. Therefore, our
results strongly argue against a direct role of endogenous NT3 in the
induction of hippocampal CA1 LTP. A similar conclusion was recently
drawn by Kokaia et al. (1998) for LTP in the lateral perforant
path-granular cell pathway. However, it was based on results using
heterozygous +/ NT3 knock-out mice, because of the
nonviability of the homozygous / mice. Several reports document the
fact that the presence of one NT3 allele has readily measurable
functional consequences, for example, on the number of sensory neurons
or on muscles spindles (Ernfors et al., 1994 ; Airaksinen and Meyer,
1996 ; Airaksinen et al., 1996 ).
Previous findings about NT3 and synaptic transmission may then have
been caused by fast, short-term effects of NT3 through increase in
evoked EPSC amplitude or increase in miniature EPSC frequency akin to
the effects observed for BDNF of minis, not directly related to LTP
(Lohof et al., 1993 ; Lessman et al., 1994 ; Levine et al., 1995 ; Li et
al., 1998 ). Moreover, the increase of synaptic transmission by
exogenous NT3 may also have been brought about by the secondary release
of BDNF. Neurotrophins can trigger the release of other neurotrophins
in dissociated cultures of hippocampal neurons (Canossa et al., 1997 )
and PC12 cells (Kruttgen et al., 1998 ). Neurotrophin-induced
neurotrophin release could therefore not only be an explanation of the
NT3 results, but it could also constitute an important factor during
normal LTP induction. Still, the lack of any effects of NT3 blockade on
LTP makes it highly unlikely that this neurotrophin is directly
involved in LTP or that BDNF-induced release of other members of the
neurotrophin family is involved in LTP induction.
Stimulus dependency
Interestingly, blocking of BDNF by antibodies only impaired LTP
induced by theta-burst stimulation but not by tetanic stimulation, whereas in BDNF knock-out mice, tetanic stimulation-induced LTP was
strongly impaired (Korte et al., 1995 , 1996 ; Patterson et al., 1996 ).
One possible explanation for the failure of BDNF antibodies to block
tetanus-induced LTP is that BDNF levels after a tetanus might exceed
the buffering capacities of the antibody in the tissue at the critical
time point. In fact, a number of reports showing that BDNF is released
in an activity-dependent manner (Blöchl and Thoenen 1995 ;
Blöchl et al., 1995 ; Thoenen, 1995 ) would predict that BDNF
concentrations are considerably higher after a tetanus than after TBS,
thereby providing a straightforward explanation for this observation.
A second explanation is that tetanus and TBS activate different
signaling pathways that are necessary for LTP induction (Kang et al.,
1997 ). Small differences in stimulation paradigms are known to trigger
different signaling pathways leading to potentiation, depotentiation,
or depression of synapses (Stäubli and Chun, 1996 ; Xu et al.,
1998 ). Thus, unlike tetanic stimulation, TBS could act through a
pathway that involves immediate BDNF effects. In particular,
application of exogenous BDNF can occlude subsequent potentiation
induced by TBS but not by tetanus (Kang et al., 1997 ). However, because
tetanic stimulation-induced LTP was so strongly diminished in BDNF
knock-out mice, these additional signaling pathway(s) would have to
depend on the constitutive presence of BDNF. BDNF could activate gene
expression through cAMP-response element binding protein, an important
component of LTP in hippocampus (Bourtchuladze et al., 1994 ; Finkbeiner
et al., 1997 ). Thus, these additional pathways in LTP may be impaired
and not be activated by tetanic stimulation in BDNF knock-out mice
while they were active when endogenous BNDF was blocked by antibodies
only for a short period of time.
Time dependency of BDNF requirement
A major question concerning the role of BDNF in LTP is the time
period during which BDNF has to be present to exert its effects. One
hypothesis is that BDNF acts as a retrograde messenger that is released
during LTP induction from the dendrites of pyramidal neurons and
subsequently induces the potentiation of synaptic transmission. Direct
evidence proving this hypothesis is still missing. Using the BDNF
antibody, we could acutely block endogenous BDNF during different time
periods relative to the induction of LTP to determine when endogenous
BDNF is needed for induction or expression of LTP. Our results show
that the presence of BDNF antibodies in the superfusion solution for 80 min before LTP induction significantly reduced LTP induced by TBS from
the beginning, which suggests that BDNF is needed during the induction
process or before. Figurov et al. (1996) have recently described for
young animals that BDNF may influence LTP by changing the effectiveness
of tetanic stimulation or TBS via facilitation of synaptic
transmission. This effect also led to enhanced paired-pulse
facilitation at short interpulse intervals. In our experiments,
blockade of BDNF had no measurable effects on basic synaptic
transmission (Figs. 1, 2) or on synaptic depression measured during TBS
or tetanus stimulation. BDNF therefore seems to affect LTP induction
directly rather than by changing the effectiveness of the LTP-inducing stimulus.
Infusion of the antibody starting at different time points after TBS
did not significantly reduce early (90 min after TBS) or late (up to 3 hr after TBS) LTP. Although in the 10 min postapplication experiment
the larger variability of the data may have obscured a potential
significant reduction in LTP by the antibodies, later stages of LTP (up
to 3 hr after TBS) clearly remained unaffected when the antibodies were
applied 30 or 60 min after TBS. Endogenous BDNF therefore seems to be
only required within a short time period before (80 min) or around the
time of induction of TBS-induced LTP. Assuming similar short
penetration times of the BDNF antibody, these results seem to be in
contrast to the results obtained by Kang et al. (1997) . Using TrkB-IgG
fusion proteins, they found that the application 30-60 min after LTP
could still block late phase of LTP, whereas later application had no
effect. Because in these experiments a different tetanic stimulation
protocol (1 sec at 100 Hz, three times, 5 min apart) was used to induce late phase LTP, this could indicate that the pattern of stimulation might have relevant consequences on the effect of BDNF on later stages
of LTP. Another explanation for the different findings may be
differences between the onset of blocking in the two sets of
experiments. A delayed onset of blocking in the postapplication experiments with the antibody could exceed a potential critical time
window during which BDNF is needed. Unfortunately, the question of when
the onset of the critical blocking concentration of the antibodies
within tissue is reached cannot conclusively be answered. Thus,
postapplication experiments in which the antibodies were applied after
LTP induction can only give a rough estimate of the temporal
requirements of BDNF for LTP.
In summary, our results provide clear evidence that endogenous BDNF
plays a unique and specific role in LTP. We could show that, under the
same stimulus conditions and similar blocking antibody concentrations,
other neurotrophins are not involved in CA1 LTP. Our study demonstrates
that BDNF affects LTP directly and not via secondary effects through
induced release of other neurotrophins. Although the exact mechanism of
the BDNF action still remains unclear, our results further show that
the lack of BDNF for a relatively short period of time, before but not after LTP-induction, is sufficient to block LTP. This seems to point
toward the possibility that BDNF is important during LTP induction.
However, the need for a constitutive activation of TrkB receptors
before LTP induction cannot be excluded and may be very important for
the activation of other LTP relevant pathways.
 |
FOOTNOTES |
Received May 5, 1999; revised June 28, 1999; accepted June 30, 1999.
This work was supported in part by the Deutsche Forschungsgemeinschaft
(SFB391) and the European Community Biotech Program (T.B.). We thank
Volker Staiger for excellent technical assistance, Martin Korte for
critical comments on this manuscript, and Ilse Bartke at Roche
Diagnostics (Penzberg, Germany) for providing us with the monoclonal
neurotrophin antibodies.
G. C.'s present address: Center for Neuroscience, The University of
Edinburgh, Edinburgh EH8 9LE, UK.
Correspondence should be addressed to Dr. Tobias Bonhoeffer,
Max-Planck-Institut für Neurobiologie, Am Klopferspitz 18 A, 82152 München-Martinsried, Germany.
 |
REFERENCES |
-
Airaksinen MS,
Meyer M
(1996)
Most classes of dorsal root ganglion neurons are severely depleted but not absent in mice lacking neurotrophin-3.
Neuroscience
73:907-911[Web of Science][Medline].
-
Airaksinen MS,
Koltzenburg M,
Lewin GR,
Masu Y,
Helbig C,
Wolf E,
Brem G,
Toyka KV,
Thoenen H,
Meyer M
(1996)
Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation.
Neuron
16:287-295[Web of Science][Medline].
-
Berninger B,
Poo M-M
(1996)
Fast action of neurotrophic factors.
Curr Opin Neurobiol
6:324-330[Web of Science][Medline].
-
Blöchl A,
Thoenen H
(1995)
Characterization of nerve growth factor (NGF) release from hippocampal neurons: evidence for a constitutive and an unconventional sodium-dependent regulated pathway.
Eur J Neurosci
7:1220-1228[Web of Science][Medline].
-
Blöchl A,
Berninger B,
Berzaghi M,
Castrén E,
Lindholm D,
Thoenen H
(1995)
Neurotrophins as mediators of neuronal plasticity.
In: Life and death in the nervous system (Ibanez CF,
ed), pp 260-272. Oxford: Elsevier.
-
Bonhoeffer T
(1996)
Neurotrophins and activity-dependent development of the neocortex.
Curr Opin Neurobiol
6:119-126[Web of Science][Medline].
-
Bourtchuladze R,
Frenguelli B,
Blendy J,
Cioffi D,
Schutz G,
Silva AJ
(1994)
Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein.
Cell
79:59-68[Web of Science][Medline].
-
Canossa M,
Griesbeck O,
Berninger B,
Campana G,
Kolbeck R,
Thoenen H
(1997)
Neurotrophin release by neurotrophins; implications for activity dependent neuronal plasticity.
Proc Natl Acad Sci USA
94:13279-13286[Abstract/Free Full Text].
-
Castrén E,
Zafra F,
Thoenen H,
Lindholm D
(1992)
Light regulates expression of brain-derived neurotrophic factor mRNA in the visual cortex.
Proc Natl Acad Sci USA
89:9444-9448[Abstract/Free Full Text].
-
Davies AM
(1994)
The role of neurotrophins in the developing nervous system.
J Neurobiol
25:1334-1349[Web of Science][Medline].
-
Dechant G,
Biffo S,
Okazawa H,
Kolbeck R,
Pottgiesser J,
Barde Y-A
(1993)
Expression and binding characteristics of the BDNF receptor chick trkB.
Development
119:545-558[Abstract].
-
Dragunow M,
Beilharz E,
Mason B,
Lawlor P,
Abraham W,
Gluckman P
(1993)
Brain-derived neurotrophic factor expression after long-term potentiation.
Neurosci Lett
160:232-236[Web of Science][Medline].
-
Ernfors P,
Wetmore C,
Olsom L,
Persson H
(1990)
Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the NGF family.
Neuron
5:511-526[Web of Science][Medline].
-
Ernfors P,
Lee KF,
Kucera J,
Jaenisch R
(1994)
Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferents.
Cell
77:503-512[Web of Science][Medline].
-
Figurov A,
Pozzo-Miller LD,
Olafsson P,
Wang T,
Lu B
(1996)
Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus.
Nature
381:706-709[Medline].
-
Finkbeiner S,
Tavazoie SF,
Maloratsky A,
Jacobs KM,
Harris KM,
Greenberg ME
(1997)
CREB: a major mediator of neuronal neurotrophin responses.
Neuron
19:1031-1047[Web of Science][Medline].
-
Gaese F,
Kolbeck R,
Barde Y-A
(1994)
Sensory ganglia require neurotrophin-3 early in development.
Development
120:1613-1619[Abstract].
-
Griesbeck O,
Blöchl A,
Carnahan JF,
Nawa H,
Thoenen H
(1995)
Characterization of brain-derived neurotrophic factor (BDNF) secretion from hippocampal neurons.
Soc Neurosci Abstr
21:417.
-
Hofer M,
Pagliusi SR,
Hohn A,
Leibrock J,
Barde YA
(1990)
Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain.
EMBO J
9:2459-2464[Web of Science][Medline].
-
Kang H,
Schuman EM
(1995)
Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus.
Science
267:1658-1662[Abstract/Free Full Text].
-
Kang H,
Jia LZ,
Suh K-Y,
Tang L,
Schuman EM
(1996)
Determinants of BDNF-induced hippocampal plasticity: role of the trkB receptor and the kinetics of neurotrophin delivery.
Learn Mem
3:188-196[Abstract/Free Full Text].
-
Kang H,
Welcher AA,
Shelton D,
Schuman EM
(1997)
Neurotrophins and time: different roles for trkB signaling in hippocampal long-term potentiation.
Neuron
19:653-664[Web of Science][Medline].
-
Katz B,
Miledi R
(1968)
The role of calcium in neuromuscular facilitation.
J Physiol (Lond)
195:481-492[Abstract/Free Full Text].
-
Klein R,
Lamballe F,
Bryant S,
Barbacid M
(1992)
The trkB tyrosine protein kinase is a receptor for neurotrophin-4.
Neuron
8:947-956[Web of Science][Medline].
-
Knipper M,
Berzaghi M,
Blöchl A,
Breer H,
Thoenen H,
Lindholm D
(1994)
Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus.
Eur J Neurosci
6:668-671[Web of Science][Medline].
-
Kokaia M,
Asztely F,
Olofsdotter K,
Balet Sindreu C,
Kullmann DM,
Olle Lindvall
(1998)
Endogenous neurotrophin-3 regulates short-term plasticity at lateral perforant path-granule cell synapses.
J Neurosci
18:8730-8739[Abstract/Free Full Text].
-
Kolbeck R,
Bartke I,
Eberle W,
Barde YA
(1999)
Brain-derived neurotrophic factor (BDNF) levels in the nervous system of wild-type and neurotrophin gene mutant mice.
J Neurochem
72:1930-1938[Web of Science][Medline].
-
Korte M,
Carroll P,
Wolff E,
Brem G,
Thoenen H,
Bonhoeffer T
(1995)
Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Proc Natl Acad Sci USA
92:8856-8860[Abstract/Free Full Text].
-
Korte M,
Griesbeck O,
Gravel C,
Carroll P,
Staiger V,
Thoenen H,
Bonhoeffer T
(1996)
Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice.
Proc Natl Acad Sci USA
93:12547-12552[Abstract/Free Full Text].
-
Kruttgen A,
Moller JC,
Heymach JV,
Shooter EM
(1998)
Neurotrophins induce release of neurotrophins by the secretory pathway.
Proc Natl Acad Sci USA
95:9614-9619[Abstract/Free Full Text].
-
Lamballe F,
Smeyne RJ,
Barbacid M
(1994)
Developmental expression of trkC, the neurotrophin-3 receptor, in the mammalian nervous system.
J Neurosci
14:14-28[Abstract].
-
Lessmann V,
Gottman K,
Heumann R
(1994)
BDNF and NT-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurons.
NeuroReport
6:21-25[Web of Science][Medline].
-
Levine ES,
Dreyfus CF,
Black IB,
Plummer MR
(1995)
Brain-derived neurotrophic factor rapidly enhances synaptic transmission in hippocampal neurons via postsynaptic tyrosine kinase receptors.
Proc Natl Acad Sci USA
92:8074-8077[Abstract/Free Full Text].
-
Lewin G,
Barde YA
(1996)
Physiology of the neurotrophins.
Annu Rev Neurosci
19:289-317[Web of Science][Medline].
-
Li Y-X,
Xu Y,
Ju D,
Lester HA,
Davidson N,
Schuman EM
(1998)
Expression of a dominant negative TrkB receptor, T1, reveals a requirement for presynaptic signaling in BDNF-induced synaptic potentiation in cultured hippocampal neurons.
Proc Natl Acad Sci USA
95:10884-10889[Abstract/Free Full Text].
-
Lindholm D,
Castren E,
Berzaghi M,
Blöchl A,
Thoenen H
(1994)
Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain- implications for neuronal plasticity.
J Neurobiol
25:1362-1372[Web of Science][Medline].
-
Linnarsson S,
Bjorklund A,
Ernfors P
(1997)
Learning deficit in BDNF mutant mice.
Eur J Neurosci
9:2581-2587[Web of Science][Medline].
-
Lo DC
(1995)
Neurotrophic factors and synaptic plasticity.
Neuron
15:979-981[Web of Science][Medline].
-
Lohof AM,
Ip NY,
Poo M-M
(1993)
Potentiation of developing neuromuscular synapses by neurotrophins NT-3 and BDNF.
Nature
363:350-353[Medline].
-
Maisonpierre PC,
Belluscio L,
Friedman B,
Alderson RF,
Wiegand SJ,
Furth ME,
Lindsay RM,
Yancopoulos GD
(1990)
NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression.
Neuron
5:501-509[Web of Science][Medline].
-
Martinez A,
Alcantara S,
Borrell V,
Delrio JA,
Blasi J,
Otal R,
Campos N,
Boronat A,
Barbacid M,
Silossantiago I,
Soriano E
(1998)
TrkB and TrkC signaling are required for maturation and synaptogenesis of hippocampal connection.
J Neurosci
18:7336-7350[Abstract/Free Full Text].
-
Patterson SL,
Grover LM,
Schwartzkroin PA,
Bothwell M
(1992)
Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs.
Neuron
9:1080-1088.
-
Patterson SL,
Abel T,
Deuel TAA,
Martin KC,
Rose JC,
Kandel ER
(1996)
Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice.
Neuron
16:1137-1145[Web of Science][Medline].
-
Shelton DL,
Sutherland J,
Gripp J,
Camerato T,
Armanini MP,
Phillips HS,
Carroll K,
Spencer SD,
Levinson AD
(1995)
Human trks: molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins.
J Neurosci
15:477-491[Abstract].
-
Stäubli U,
Chun D
(1996)
Factors regulating the reversibility of long-term potentiation.
J Neurosci
16:853-860[Abstract/Free Full Text].
-
Thoenen H
(1995)
Neurotrophins and neuronal plasticity.
Science
270:593-598[Abstract/Free Full Text].
-
Timmusk T,
Belluardo N,
Metsis M,
Persson H
(1993)
Widespread and developmentally regulated expression of neurotrophin-4 mRNA in rat brain and peripheral tissues.
Eur J Neurosci
5:605-613[Web of Science][Medline].
-
Wetmore C,
Ernfors P,
Persson H,
Olson L
(1989)
Localization of BDNF mRNA to neurons in the brain by in situ hybridization.
Exp Neurol
109:141-152.
-
Xu L,
Anwyl R,
Rowan MJ
(1998)
Spatial exploration induces a persistent reversal of long-term potentiation in rat hippocampus.
Nature
394:891-894[Medline].
-
Zafra F,
Hengerer B,
Leibrock J,
Thoenen H,
Lindholm D
(1990)
Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors.
EMBO J
9:3545-3550[Web of Science][Medline].
-
Zafra F,
Castrén E,
Thoenen H,
Lindholm D
(1991)
Interplay between glutamate and
-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons.
Proc Natl Acad Sci USA
88:10037-10041[Abstract/Free Full Text]. -
Zucker RS
(1989)
Short-term synaptic plasticity.
Annu Rev Neurosci
12:13-31[Web of Science][Medline].
Copyright © 1999 Society for Neuroscience 0270-6474/99/19187983-08$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
U. Faraguna, V. V. Vyazovskiy, A. B. Nelson, G. Tononi, and C. Cirelli
A Causal Role for Brain-Derived Neurotrophic Factor in the Homeostatic Regulation of Sleep
J. Neurosci.,
April 9, 2008;
28(15):
4088 - 4095.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Lauterborn, C. S. Rex, E. Kramar, L. Y. Chen, V. Pandyarajan, G. Lynch, and C. M. Gall
Brain-Derived Neurotrophic Factor Rescues Synaptic Plasticity in a Mouse Model of Fragile X Syndrome
J. Neurosci.,
October 3, 2007;
27(40):
10685 - 10694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kolarow, T. Brigadski, and V. Lessmann
Postsynaptic Secretion of BDNF and NT-3 from Hippocampal Neurons Depends on Calcium Calmodulin Kinase II Signaling and Proceeds via Delayed Fusion Pore Opening
J. Neurosci.,
September 26, 2007;
27(39):
10350 - 10364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Amaral and L. Pozzo-Miller
TRPC3 Channels Are Necessary for Brain-Derived Neurotrophic Factor to Activate a Nonselective Cationic Current and to Induce Dendritic Spine Formation
J. Neurosci.,
May 9, 2007;
27(19):
5179 - 5189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Caldeira, C. V. Melo, D. B. Pereira, R. Carvalho, S. S. Correia, D. S. Backos, A. L. Carvalho, J. A. Esteban, and C. B. Duarte
Brain-derived Neurotrophic Factor Regulates the Expression and Synaptic Delivery of{alpha}-Amino-3-hydroxy-5-methyl-4-isoxazole Propionic Acid Receptor Subunits in Hippocampal Neurons
J. Biol. Chem.,
April 27, 2007;
282(17):
12619 - 12628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Lynch, E. A. Kramar, C. S. Rex, Y. Jia, D. Chappas, C. M. Gall, and D. A. Simmons
Brain-Derived Neurotrophic Factor Restores Synaptic Plasticity in a Knock-In Mouse Model of Huntington's Disease
J. Neurosci.,
April 18, 2007;
27(16):
4424 - 4434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Rex, C.-Y. Lin, E. A. Kramar, L. Y. Chen, C. M. Gall, and G. Lynch
Brain-Derived Neurotrophic Factor Promotes Long-Term Potentiation-Related Cytoskeletal Changes in Adult Hippocampus
J. Neurosci.,
March 14, 2007;
27(11):
3017 - 3029.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-T. Zhang, L.-Y. Li, X.-L. Zou, X.-B. Song, Y.-L. Hu, Z.-T. Feng, and T. T.-H. Wang
Immunohistochemical Distribution of NGF, BDNF, NT-3, and NT-4 in Adult Rhesus Monkey Brains
J. Histochem. Cytochem.,
January 1, 2007;
55(1):
1 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Sharma, C. M. Sherff, S. Stough, V. Hsuan, and T. J. Carew
A tropomyosin-related kinase B ligand is required for ERK activation, long-term synaptic facilitation, and long-term memory in Aplysia
PNAS,
September 19, 2006;
103(38):
14206 - 14210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Rex, J. C. Lauterborn, C.-Y. Lin, E. A. Kramar, G. A. Rogers, C. M. Gall, and G. Lynch
Restoration of Long-Term Potentiation in Middle-Aged Hippocampus After Induction of Brain-Derived Neurotrophic Factor
J Neurophysiol,
August 1, 2006;
96(2):
677 - 685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. J. Tyler, X.-l. Zhang, K. Hartman, J. Winterer, W. Muller, P. K. Stanton, and L. Pozzo-Miller
BDNF increases release probability and the size of a rapidly recycling vesicle pool within rat hippocampal excitatory synapses
J. Physiol.,
August 1, 2006;
574(3):
787 - 803.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Shimazu, M. Zhao, K. Sakata, S. Akbarian, B. Bates, R. Jaenisch, and B. Lu
NT-3 facilitates hippocampal plasticity and learning and memory by regulating neurogenesis
Learn. Mem.,
May 1, 2006;
13(3):
307 - 315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gartner, D. G. Polnau, V. Staiger, C. Sciarretta, L. Minichiello, H. Thoenen, T. Bonhoeffer, and M. Korte
Hippocampal long-term potentiation is supported by presynaptic and postsynaptic tyrosine receptor kinase B-mediated phospholipase Cgamma signaling.
J. Neurosci.,
March 29, 2006;
26(13):
3496 - 3504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.-M. Vouimba and G. Richter-Levin
Physiological Dissociation in Hippocampal Subregions in Response to Amygdala Stimulation
Cereb Cortex,
November 1, 2005;
15(11):
1815 - 1821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Rosch, R. Schweigreiter, T. Bonhoeffer, Y.-A. Barde, and M. Korte
The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus
PNAS,
May 17, 2005;
102(20):
7362 - 7367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Hwang, M.-H. Park, S.-Y. Choi, and J.-Y. Koh
Activation of the Trk Signaling Pathway by Extracellular Zinc: ROLE OF METALLOPROTEINASES
J. Biol. Chem.,
March 25, 2005;
280(12):
11995 - 12001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Kramar, B. Lin, C.-Y. Lin, A. C. Arai, C. M. Gall, and G. Lynch
A Novel Mechanism for the Facilitation of Theta-Induced Long-Term Potentiation by Brain-Derived Neurotrophic Factor
J. Neurosci.,
June 2, 2004;
24(22):
5151 - 5161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Diogenes, C. C. Fernandes, A. M. Sebastiao, and J. A. Ribeiro
Activation of Adenosine A2A Receptor Facilitates Brain-Derived Neurotrophic Factor Modulation of Synaptic Transmission in Hippocampal Slices
J. Neurosci.,
March 24, 2004;
24(12):
2905 - 2913.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Greenwood and R. Parasuraman
Normal Genetic Variation, Cognition, and Aging
Behav Cogn Neurosci Rev,
December 1, 2003;
2(4):
278 - 306.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Hibbert, S. J. Morris, N. G. Seidah, and R. A. Murphy
Neurotrophin-4, Alone or Heterodimerized with Brain-derived Neurotrophic Factor, Is Sorted to the Constitutive Secretory Pathway
J. Biol. Chem.,
November 28, 2003;
278(48):
48129 - 48136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Alder, S. Thakker-Varia, D. A. Bangasser, M. Kuroiwa, M. R. Plummer, T. J. Shors, and I. B. Black
Brain-Derived Neurotrophic Factor-Induced Gene Expression Reveals Novel Actions of VGF in Hippocampal Synaptic Plasticity
J. Neurosci.,
November 26, 2003;
23(34):
10800 - 10808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Gustafsson, O. Lindvall, and Z. Kokaia
Intraventricular Infusion of TrkB-Fc Fusion Protein Promotes Ischemia-Induced Neurogenesis in Adult Rat Dentate Gyrus
Stroke,
November 1, 2003;
34(11):
2710 - 2715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Balkowiec and D. M. Katz
Cellular Mechanisms Regulating Activity-Dependent Release of Native Brain-Derived Neurotrophic Factor from Hippocampal Neurons
J. Neurosci.,
December 1, 2002;
22(23):
10399 - 10407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Messaoudi, S.-W. Ying, T. Kanhema, S. D. Croll, and C. R. Bramham
Brain-Derived Neurotrophic Factor Triggers Transcription-Dependent, Late Phase Long-Term Potentiation In Vivo
J. Neurosci.,
September 1, 2002;
22(17):
7453 - 7461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Otmakhov and J. E. Lisman
Postsynaptic Application of a cAMP Analogue Reverses Long-Term Potentiation in Hippocampal CA1 Pyramidal Neurons
J Neurophysiol,
June 1, 2002;
87(6):
3018 - 3032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gartner and V. Staiger
Neurotrophin secretion from hippocampal neurons evoked by long-term-potentiation-inducing electrical stimulation patterns
PNAS,
April 30, 2002;
99(9):
6386 - 6391.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-W. Ying, M. Futter, K. Rosenblum, M. J. Webber, S. P. Hunt, T. V. P. Bliss, and C. R. Bramham
Brain-Derived Neurotrophic Factor Induces Long-Term Potentiation in Intact Adult Hippocampus: Requirement for ERK Activation Coupled to CREB and Upregulation of Arc Synthesis
J. Neurosci.,
March 1, 2002;
22(5):
1532 - 1540.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kovalchuk, E. Hanse, K. W. Kafitz, and A. Konnerth
Postsynaptic Induction of BDNF-Mediated Long-Term Potentiation
Science,
March 1, 2002;
295(5560):
1729 - 1734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Kossel, S. B. Cambridge, U. Wagner, and T. Bonhoeffer
A caged Ab reveals an immediate/instructive effect of BDNF during hippocampal synaptic potentiation
PNAS,
November 20, 2001;
(2001)
251326998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Auld, F. Mennicken, and R. Quirion
Nerve Growth Factor Rapidly Induces Prolonged Acetylcholine Release from Cultured Basal Forebrain Neurons: Differentiation between Neuromodulatory and Neurotrophic Influences
J. Neurosci.,
May 15, 2001;
21(10):
3375 - 3382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bibel and Y.-A. Barde
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Genes & Dev.,
December 1, 2000;
14(23):
2919 - 2937.
[Full Text]
|
 |
|

|
 |

|
 |
 
V. L. Arvanov, B. S. Seebach, and L. M. Mendell
NT-3 Evokes an LTP-Like Facilitation of AMPA/Kainate Receptor-Mediated Synaptic Transmission in the Neonatal Rat Spinal Cord
J Neurophysiol,
August 1, 2000;
84(2):
752 - 758.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. F. Farhadi, S. J. Mowla, K. Petrecca, S. J. Morris, N. G. Seidah, and R. A. Murphy
Neurotrophin-3 Sorts to the Constitutive Secretory Pathway of Hippocampal Neurons and Is Diverted to the Regulated Secretory Pathway by Coexpression with Brain-Derived Neurotrophic Factor
J. Neurosci.,
June 1, 2000;
20(11):
4059 - 4068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Muller, Z. Djebbara-Hannas, P. Jourdain, L. Vutskits, P. Durbec, G. Rougon, and J. Z. Kiss
Brain-derived neurotrophic factor restores long-term potentiation in polysialic acid-neural cell adhesion molecule-deficient hippocampus
PNAS,
April 11, 2000;
97(8):
4315 - 4320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Kossel, S. B. Cambridge, U. Wagner, and T. Bonhoeffer
A caged Ab reveals an immediate/instructive effect of BDNF during hippocampal synaptic potentiation
PNAS,
December 4, 2001;
98(25):
14702 - 14707.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|